GentiBio

GentiBio is pioneering the development of engineered Treg (EngTreg) therapies, aiming to provide curative treatments for autoimmune and inflammatory diseases like Type 1 diabetes. The company has built a dual-platform strategy encompassing both autologous and proprietary 'off-the-shelf' allogeneic Tregs, engineered for specificity, stability, and immune evasion. Having advanced its lead candidate into Phase 1 clinical trials and secured key regulatory designations, GentiBio is positioned as a leader in translating Treg biology into scalable, transformative cell therapies. Its approach seeks to replace broad immunosuppression with targeted, tissue-restricted immune resetting and healing.

Modular engineering platform for creating engineered regulatory T-cells (EngTregs) with enhanced specificity, stability, and survival. Includes proprietary immune-evasive technology for off-the-shelf allogeneic Tregs and scalable manufacturing processes for both autologous and allogeneic approaches.

GentiBio operates in the competitive and rapidly evolving field of regulatory T-cell (Treg) therapy. It faces competition from other biotechs developing autologous or allogeneic Tregs for autoimmune diseases, as well as from companies exploring alternative regulatory cell types (e.g., CAR-Tregs, myeloid cells). Large pharmaceutical companies with immunology portfolios also represent potential competitors or future partners. GentiBio aims to differentiate through its integrated platform focusing on specificity, stability, and a proprietary approach to allogeneic immune evasion.